1. Ersoy F.F., Karayalcin U., Karayalcin B., Sapan M., Bozcuk H., Suleymanlar G., Yakupoglu G. Transfer of Native Insulin through the Peritoneal Membrane during CAPD in Diabetic and Non-Diabetic Patients. Advances in Peritoneal Dialysis. 1995;11: 119-22.
2. Ustun H., Ersoy F.F., Sezer T., Ozcan S., Bozcuk H., Yegin O., Balci M., Suleymanlar G., Yakupoglu G. Effect of Cefodizime on peritoneal mononuclear and polymorphonuclear cell chemotaxis. Advances in Peritoneal Dialysis. 1998;14:154-7.
3. Aslan M., Yucel G., Bozcuk H., Savas B. The effect of recombinant human granulocyte/macrophage-colony-stimulating factor (rHu GM-CSF) and rHu G-CSF administration on neutrophil chemiluminescence assay in patients following cyclic chemotherapy. Cancer I
4. Bozcuk H., Turner B, Tsetis D.,Thomas JM.,Chan O.,Reznek R.,Ravi R.,Hendry WF.,Oliver RTD. The potential of day 21 CT scan and 3 dimensional construction in predicting need for post chemotherapy surgery in nonseminomatous germ cell tumour. British Jour
5. Bozcuk H, Uslu G, Pestereli E, Samur M, Ozdogan M, Karaveli S, Sargin F, Savas B. Predictors of distant metastasis at presentation in Breast Cancer: A study also evaluating associations among common biological indicators. Breast Cancer Research and Tre
6. Bozcuk H, Martin C. Does treatment delay affect survival in non-small Lung Cancer? A retrospective analysis from a single U.K. centre. Lung Cancer, 2001; 34(2): 243-52.
7. Goonewardane T. I.., Bozcuk H., Oliver R.T.D., Barua J., Philip T., Mair G., Gibbs S. Phase ½ study of synchronous Methotrexate, Cisplatin, Vincristine (MOPq10) chemotherapy and radiation for patients with locally advanced Bladder Cancer. Urologia Inte
8. Samur M, Bozcuk H, Kara A, Ozdogan M, Savas B. Factors associated with utilisation of unproven cancer therapies in Turkey. Supportive Care in Cancer 2001; 9(6): 452-8.
9. Ustun H, Ustun M, Sindel T, Yilmaz S, Bozcuk H, Karpuzoglu G, Savas B. Lipiodol chemoembolization and additional tamoxifen and verapamil as chemosensitizers in unresectable hepatocellular carcinoma with immunohistochemically P-glycoprotein positive cas
10. Bozcuk H, Erdoğan V, Eken C, Çıplak E, Samur M, Ozdogan M, Savas B. Does awareness of diagnosis make any difference to quality of life? The determinants of emotional functioning in a group of cancer patients in Turkey. Supportive Care in Cancer, 2002;
11. Samur M, Bozcuk H, Dalmaz G, Karaveli Ş, Köseoğlu FG, Çolak T, Peştereli E. Treatment delay in breast cancer; does it really have an impact on prognosis? Turkish Journal of Cancer, 2002; 32(4): 138-47.
12. Bozcuk H, Kolağası O, Samur M, Yıldız M, Özdoğan M, Artaç M, Savas B. A brief information sheet on opioid effects improves quality of life in cancer patients on opioids. Internet journal of pain, symptom control and palliative care, 2003; 2(2)
13. Samur M, Bozcuk H. A paradigm shift in adjuvant treatment of receptor positive premenapausal breast cancer patients? Not yet! (Letter to the editor). Journal of Clinical Oncology, 2003; 21(12): 2444.
14. Özdoğan M, Samur M, Bozcuk H, Sagtas E, Yıldız M, Artaç M, Savas B. Durable remission of leptomeningeal metastasis of breast cancer with letrozole; a case report and implications of biomarkers on treatment selection. Japanese Journal of Clinical Onco
15. Coban E, Samur M, Bozcuk H, Ozdogan M. The value of CEA and CA19-9 in detecting cancer in a group of “High Risk” subjects with gastrointestinal symptoms. International Journal of Biological Markers, 2003; 18 (3): 177-81.
16. Samur M, Bozcuk H, Karaveli Ş, Peştereli E, Özdoğan M, Yıldız M, Artaç M, Savaş B. Reevaluation of baseline staging tests in breast cancer; what should be the standard? Turkish Journal of Cancer, 2003; 33(3):150-3.
17. Samur M, Karaveli S, Bozcuk H, Pestereli E, Ozdogan M, Yildiz M, Artac M, Savas B. A novel method of reporting c-erb-B2 overexpression: correlation with grade but not with other prognostic parameters in breast cancer. Turkish Journal of Medical Scienc
18. Coban E, Ozdogan M, Tuncer M, Bozcuk H, Ersoy F. The Value of Low-Dose Intraperitoneal Immunoglobulin administration in the treatment of Peritoneal Dialysis Related Peritonitis. Journal of Nephrology, 2004; 17 (3): 427-430.
19. Sanlioglu A, Aydin C, Bozcuk H, Terzioglu E, Luleci G, Sanlioglu S. Fundamental principles of tumor necrosis factor- alpha gene therapy approach and implications for patients with lung carcinoma. Lung Cancer,2004; 44 (2): 199-211.
20. Ozdogan M, Samur M, Bozcuk H, Coban E, Artac M, Kara A, Topcu Z, Sualp Y, Savas B. Do not tell approach: which factors affect relatives’ attitudes against honest disclosure of diagnosis to cancer patients? Supportive Care in Cancer, 2004; 12 (7): 497-
21. Bozcuk H, Koyuncu E, Yıldız M, Samur M, Özdoğan M, Artaç M, Çoban E, Savaş B. A simple and accurate prediction model to estimate the intrahospital mortality risk for hospitalised cancer patients. International Journal of Clinical Practice, 2004; 58 (1
22. Bozcuk H, Bilge U, Koyuncu E, Gulkesen H. An application of Genetic Algorithm in conjunction with other data mining methods for estimating outcome after hospitalization in cancer patients. Medical Science Monitor, 2004; 10(6): CR246-251.
23. Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdogan M, Artac M, Altunbas H, Akan I, Savas B. Tumor Necrosis Factor-alpha, Interleukin-6 and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemo
24. Ozdogan M, Samur M, Bozcuk H, Aydın H, Coban E, Savas B. Venlafaxine for treatment of chemotherapy induced neuropathic pain. Turkish Journal of Cancer, 2004; 34 (3): 110-113.
25. Ozdogan M, Samur M, Bozcuk H, Coban E, Artac M, Savas B. Is the third line chemotherapy feasible for non small cell lung cancer? A retrospective study. Turkish Journal of Cancer, 2004; 34(1):19-23.
26. Bozcuk H, Gumus A, Ozbilim G, Sarper A, Kucukosmanoglu I, Artac M, Ozdogan M, Samur M, Kaya A, Savas B. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-sma
27. Artac M, Bozcuk H, Ozdogan M, Demiral AN, Sarper A, Samur M, Savas B. Different clinical features of primary and secondary tumours in patients with multiple malignancies. Tumori, 2005;91(4):317-320.
28. Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance / consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)?: A meta-analysis of the published randomized controlled trials. Cancer, 2005; 104(12): 2650-2657.
29. Yildiz M, Ozenci CC, Akan I, Akan S, Sati L, Demir R, Savas B, Ozben T, Samur M, Ozdogan M, Artac M, Bozcuk H. Zoledronic acid induces apoptosis in vitro: its association with Multidrug Resıstance Protein-1 and evidence for synergy with vinblastine.
30. Bozcuk H, Dalmis B, Samur M, Ozdogan M, Artac M, Savas B. Quality of life in patients with advanced non-small cell lung cancer. Cancer Nursing, 2006; 29(2): 104-110.
31. Bozcuk H, Artac M, Kara A, Ozdogan M, Sualp Y, Topcu Z, Karaagacli A, Yildiz M, Savas B. Does music exposure during chemotherapy improve quality of life in early breast cancer patients? : a pilot study. Medical Science Monitor, 2006; 12(5): CR200-205.
32. Yildiz M, Bozcuk H, Aslan A, Simsek T, Zorlu G, Artac M, Ozdogan M, Savas B, Samur M. Retrospective evaluation of weekly docetaxel in recurrent ovarian cancer: a single centre experience. The internet journal of gynecology and obstetrics, 2006; 6(1).
33. Ozdogan M, Samur M, Artac M, Yildiz M, Savas B, Bozcuk HS. Factors related to truth-telling practice of physicians treating patients with cancer in Turkey. Journal of palliative medicine, 2006; 9(5): 1114-1119.
34. Bulent Y, Zengin N, Aydın F, İlhan M, Isikdogan A, Demir G, Aykan F, Celik I, Dane F, Ustuner Z, Boruban MC, Bozcuk H, Coskun HS, Karaoglu A, Altınbas M, Yamac D, Tek I, Budakoglu B, Utkan G, Ozdemir F, Aksoy F, Ozdemir F, Aksoy S, Ozdemir N, Akbulut
35. Ozdogan M, Bozcuk H, Coban E. Low grade inflammation in white coat hypertension. Medical Science Monitor, 2007; 13(12): CR570-573.
36. Ozturk OH, Bozcuk H, Burgucu D, Ekinci D, Ozdogan M, Akca S, Yildiz M. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line. Preliminary results of an in vitro study. Cell Biology International, 2007; 31(9): 1069-1071.
37. Bozcuk H, Gumus A, Ozbilim G, Sarper A, Kucukosmanoglu I, Ozdogan M, Demircan A. Recursive partitioning analysis of mediastinal N2 lymph node involvement with selected biomarkers in operable non-small cell lung cancer: A correlative study. Biomarker I
38. Artac M, Bozcuk H. The debate over maintenance is not over in small cell lung cancer (Letter to the editor). Journal of Clinical Oncology, 2007; 25(36): 5840.
39. Korcum AF, Aksu G, Bozcuk H, Pestereli E, Simsek T. Small cell carcinoma of the cervix: a case report. Archives of Gynecology and Obstetrics, 2008; 277(4): 367-370.
40. Aksu MG, Bozcuk HS, Korcum AF. Effect of complementary and alternative medicine during radiotherapy on radiation toxicity. Support Care Cancer, 2008; 16(4): 415-419.
41. Artac M, Bozcuk H, Afacan B, Ozdogan M, Samur M. The impact of waist to hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors. Breast, 2008; 17(4): 418-422.
42. Aksu MG, Bozcuk H, Korcum AF, Sen CA, Tuncel N. The results of postoperative chemoradiotherapy in rectal cancer. Turkish Journal of Cancer, 2008; 38(1): 5-11.
43. Artac M, Pehlivan S, Akcan S, Pehlivan M, Tekinalp G, Itırlı G, Aksoy N, Ozdogan M, Savas B, Bozcuk H. The role of microsatellite instability to predict clinical benefit from irinotecan based regimens in metastatic colorectal cancer. Turkish Journal
44. Artac M, Bozcuk H, Pehlivan S, Akcan S, Pehlivan M, Sever T, Ozdogan M, Savas B. The value of XPD and XRCC1 genotype polymorhisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan based regimens. J Cancer Res Cli
45. Bozcuk H, Artac M, Ozdogan M. Correlates of benefit from neoadjuvant chemotherapy before radiotherapy in non-small cell lung cancer: a meta-analytical approach with meta-regression analysis. J BUON, 2010; 15(1): 43-50.
46. Pehlivan S, Artac M, Sever T, Bozcuk H, Kilincarslan C, Pehlivan M. Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. Cancer Gent Cytogenet, 2010; 201(2): 128-132.
47. Coşkun HS, Kargı A, Ozdogan M, Bozcuk H, Savas B. Leukocytosis, thrombocytosis and hypercalcemia as a triple paraneoplastic syndrome in a patient with squamous cell cafrcinoma of the renal pelvis. Turk J Hematol, 2010; 27: 51-52.
48. Sarper A, Titiz TA, Oz N, Arslan G, Bozcuk H, Demircan A. Results of carinal sleeve lobectomy and sleeve pneumonectomy for lung carcinoma. Turkish J Thorac Cardiovasc Surg, 2010; 18(4): 293-299.
49. Bozcuk H, Ozdogan M, Aykurt O, Topcuoglu F, Ozturk H, Ekinci D, Karadeniz A, Mutlu A, Burgucu D. Urginea Maritima (L.) Baker (Liliaceae) extract induces more cytotoxicity than standard chemotherapeutics in the A549non-small cell lung cancer cell line.
50. Bozcuk H, Ozdogan M. The predictors of the efficacy of high dose chemotherapy and stem cell support in the management of metastatic germ cell cancer. Bratisl Lek Listy 2011; 112(5): 296-304.
51. Artac M, Bozcuk H, Kıyıcı A, Eren OO, Boruban MC, Ozdogan M. Serum leptin level and waist to hip ratio predict the overall survival of metastatic breast cancer patients treated with aromatase inhibitors. Breast Cancer, 2011; Dec 28 (Epub ahead of pri
52. Tatlı AM, Uysal M, Goksu SS, Arslan D, Gunduz S, Ozdogan M, Coskun HS, Bozcuk H, Savas B. Primary mucinous adenocarcinoma of the bladder: complete response with FOLFOX-4 regimen. Med Oncol, 2012; 29(3): 1935-1937.
53. Senol Y, Ozdogan M, Bozcuk H. Effects and permenancy of the training program “Communication with cancer patients” on the opinions of the students. J Cancer Educ, 2012; 27(2): 338 -341.
54. Uysal M, Goksu SS, Coskun HS, Savas B, Ozdogan M, Bozcuk H. Intraarticular hemorhage due to Bevacizumab in a patient with metastatic colorectal cancer: a case report. J Med Case Rep, 2012; 6(1): 188. doi: 10.1186/1752-1947-6-188.
55. Bozcuk H, Abali H, Coskun S. Lung Cancer Committee of Turkish Oncology Group. The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. World J Surgical Oncol, 2012; 10(1): 161. do
56. Kavradim ST, Ozer ZC, Bozcuk H. Hope in people with cancer: a multivariate analysis from Turkey. J Adv Nurs, 2013; 69 (5): 1183-1196.
57. Gunduz S, Elpek GO, Uysal M, Goksu SS, Tatli M, Arslan D, Coskun HS, Bozcuk H, Savas B, Ozdogan M. Coexistance of gastric adenocarcinoma and choriocarcinoma: complete response to trastuzumab and chemotherapy. Case Rep Oncol 2012; 5(2):394-399.
58- Arslan D, Gündüz S, Tural D, Uysal M, Tatlı AM, Başsorgun Cİ, Elpek GÖ, Coşkun HŞ, Bozcuk HŞ, Savaş B. Inflammatory myofibroblastic tumor: a rarely seen submucosal lesion of the stomach. Case Rep Oncol Med. 2013;2013:328108. doi: 10.1155/2013/328108.
59- Zeybek A, Toru S, Ozbudak IH, Sarper A, Oz N, Bozcuk H, Ozbilim G, Demircan A. Clinical and pathologic prognostic factors that are influential in the survival and prognosis of lung adenocarcinomas and invasive predominant subtypes. Int Surg. 2013;98(3
60- Kargi A, Uysal M, Bozcuk H, Coskun HS, Savas B, Ozdogan M. The importance of COX-2 expression as prognostic factor in early breast cancer. J BUON. 2013;18(3):579-584.
61- Uysal M, Bozcuk H, Karakilinc H, Goksu S, Tatli AM, Gunduz S, Arslan D, Coskun HS, Savas B. Pesticides and cancer: the first incidence study conducted in Turkey. J Environ Pathol Toxicol Oncol. 2013;32(3):245-249.
62-Yildiz M, Bozcuk H, Tokgun O, Karagur ER, Aykurt O, Akca H. Cyclamen exerts cytotoxicity in solid tumor cell lines: a step towards new cancer agents? Asian Pac J Cancer Prev. 2013; 14(10): 5911-5913.
63- Uysal M, Bozcuk H, Sezgin Göksu S, Murat Tatli A, Arslan D, Gündüz S, Senol Coskun H, Ozdogan M, Savas B. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab. Biomed Pharmacother. 2014 May;68
64- Arican A, Bozkurt T, Bozcuk H, Demirkan B, Buyukberber S, Alkis N, Sanli UA, Camci C, Yildiz M, Yucel I, Uygun K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, Gemici C, Ozdemir F, Ozdener F, Pekin B. A cross-sectional survey of the diagnosis and
65-Arslan D, Bozcuk H, Gunduz S, Tural D, Tattli AM, Uysal M, Goksu SS, Bassorgun Cİ, Koral L, Coskun HS, Ozdogan M, Savas B. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging
66- Artac M, Turhal NS, Kocer M, Karabulut B, Bozcuk H, Yalcin S, Karaagac M, Gündüz S, Isik N, Uygun K. Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study. Tumori. 2014;100(2):143-148.
67- Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. Asian Pac J Cancer Prev. 2014;15(8):3801-3804.
68- Goksu SS, Gunduz S, Unal D, Uysal M, Arslan D, Tatli AM, Bozcuk H, Ozdogan M, Coskun HS. Use of blood transfusion at the end of life: does it have any effects on survival of cancer patients? Asian Pac J Cancer Prev. 2014;15(10):4251-4254.
69- Mutlu H, Gündüz S, Büyükçelik A, Yıldız O, Uysal M, Tural D, Bozcuk H, Coşkun HŞ. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b. Clin Genitour
70- Arslan D, Uysal M, Tatlı AM, Gunduz S, Goksu SS, Başsorgun Cİ, Coskun HS, Bozcuk H, Savaş B. Her-2 positive gastric cancer presented with thrombocytopenia and skin involvement: a case report. Case Rep Oncol Med. 2014;2014:194636. doi: 10.1155/2014/194
71- Tatlı AM, Coşkun HŞ, Uysal M, Arslan D, Sezgin Göksu S, Güenay Gündüz S, Cakal S, Bozcuk HŞ, Savaş B. Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma. Int J Clin Exp
72- Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H. Elucidating the correlation between treatment with tyrosine kinase inhibitors and mean platelet volume in patients with metastatic renal cell cancer. Oncol Lett. 2014;8(5):2249-2252. 73- Arslan D, Koca
74- Gunduz S, Mutlu H, Goksu SS, Arslan D, Tatli AM, Uysal M, Coskun HS, Bozcuk H, Ozdogan M, Savas B. Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma. Asian Pac J Cancer Prev. 2014;15(20):8843-8846.
75- Goksu SS, Bozcuk H, Uysal M, Ulukal E, Ay S, Karasu G, Soydas T, Coskun HS, Ozdogan M, Savas B. Determinants of opioid efficiency in cancer pain: a comprehensive multivariate analysis from a tertiary cancer centre. Asian Pac J Cancer Prev. 2014;15(21)
76- Bozcuk H, Yıldız M, Artaç M, Kocer M, Kaya Ç, Ulukal E, Ay S, Kılıç MP, Şimşek EH, Kılıçkaya P, Uçar S, Coskun HS, Savas B. A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. Su
77- Sezgin Goksu S, Gunduz S, Unal D, Uysal M, Arslan D, Tatlı AM, Bozcuk H, Ozdogan M, Coskun HS. Use of chemotherapy at the end of life in Turkey. BMC Palliat Care. 2014;13(1):51. doi: 10.1186/1472-684X-13-51. eCollection 2014
78-Yıldırım M, Duman E, Ozturk TT, Kaya V,Parlak C, Varol U,Kaya K, Yıldız M, Bozcuk H. Cancer patients’ level of knowledge about diseases and their expectations from their oncologists. TAF preventive Medicine Bulletin, 2014;13(6): 465-468.
79- Gunduz S, Ozgur O, Bozcuk H, Coşkun HS, Ozdogan M, Erkilic M, Sindel T, Yldlzs A, Ylmaz S, Boz A, Aydin F, Karayalçin B, Savas B. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatme
80- Uysal M, Ozdogan M, Kargi A, Gunduz S, Sezgin Goksu S, Murat Tatli A, Arslan D, Mutlu H, Senol Coskun H, Bozcuk H. Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual di
81- Demirelli S, Erkilic M, Oner AO, Budak ES, Gunduz S, Ozgur O, Bozcuk H, Sindel HT, Boz A. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres. Nucl Med Commun. 2015
82- Geredeli C, Artac M, Yildirim S, Inal A, Dede I, Guler T, Boruban MC, Koral L, Karaagac M, Zamani AG, Altinok T, Aribas O, Bozcuk H, Demirkazik A. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early
83- Yildirim M, Kaya V, Demirpence O, Gunduz S, Bozcuk H. Prognostic significance of p53 in gastric cancer: a meta- analysis. Asian Pac J Cancer Prev. 2015;16(1):327-332.
84- Mutlu H, Arslan D, Gündüz S, Tural D, Büyükçelik A, Cihan YB, Aslan T, Bozcuk H, Coşkun HS. The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidatio
85- Gunduz S, Mutlu H, Tural D, Yıldız Ö, Uysal M, Coskun HS, Bozcuk H. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Asia Pac J Clin Oncol. 2015. doi: 10.1111/ajco.12358. [Epub ahead of print]
86- Arslan D, Tural D, Koca T, Tastekin D, Kaymak Cerkesli A, Basaran H, Gunduz S, Murat Tatli A, Sezgin Goksu S, Uysal M, Kargi A, Kargi B, Koral L, Ibrahim Bassorgun C, Unal D, Mutlu H, Senol Coskun H, Ozdogan M, Bozcuk H. Prognostic factors in clinical
87- Mutlu H, Musri FY, Yalçın M, Kargi A, Özdogan M, Bozcuk H. Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer. J Cancer Res Ther. 2015;11(2):287-290.
88- Tural D, Kivrak SD, Mutlu H, Erkilic M, Gunduz S, Karakurt M, Musri F, Tuna S, Boz A, Aydin F, Karayalcin B, Bozcuk H, Senol CH. Is there any relation between PET-CT SUVmax value and prognostic factors in locally advanced breast cancer? J BUON. 2015;2
89- Gündüz S, Göksu SS, Arslan D, Tatli AM, Uysal M, Gündüz UR, Sevinç MM, Coşkun HS, Bozcuk H, Mutlu H, Savas B. Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant
90- Tatli AM, Arslan D, Uysal M, Goksu SS, Gunduz SG, Coskun HS, Ozdogan M, Savas B, Bozcuk HS. Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer. J Cancer Res Ther. 2015;11(4):805-809.
91- Göksu SS, Bozcuk H, Koral L, Çakar B, Gündüz S, Tatlı AM, Arslan D, Uysal M, Koçer M, Artaç M, Karabulut B, Coşkun HS, Özdoğan M, Savaş B. Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different hi
92- Gunduz S, Bozcuk H, Yıldız M, Goksu SS, Uysal M, Arslan D, Tatlı AM, Mutlu H, Coşkun HS, Ozdogan M. Line of abiraterone acetate in castration-resistant metastatic prostate cancer - Does it matter? report of a multi-institutional experience. Indian J C
93- Turkoglu MA, Vural V, Erbis H, Coskun HS, Bozcuk H, Ibis M. Liver first approach as an unusual treatment modality for rectal cancer with synchronous liver metastasis:report of a case. Gazi Med J, 2015; 26(3): 117-118.
94- Merdin A, Merdin FA, Gunduz S, Bozcuk H, Coskun HS. Opioid endocrinopathy: a clinical problem in patients with cancer pain. Exp Ther Med. 2016;11(5):1819-1822.
95- Artac M, Coskun HS, Korkmaz L, Kocer M, Turhal NS, Engin H, Dede I, Paydas S, Oksuzoglu B, Bozcuk H, Demirkazık A. Using Interferon alpha before Thyrosine kinase inhibitors may increase survival in patients with metastatic renal carcinoma: a Turkish O
96- Artac M, Uysal M, Karaagac M, Korkmaz L, Er Z, Guler T, Boruban MC, Bozcuk H. Prognostic impact of neutrophil/lymphocyte ratio, platelet count, CRP and albumin levels in metastatic colorectal cancer patients treated with FOLFIRI-Bevacizumab. J Gastroi
97- Bozcuk H, Ozcan K, Erdogan C, Mutlu H, Demir M, Coskun S. A comparative study of art therapy in cancer patients receiving chemotherapy and improvement in quality of life by watercolour painting. Complementary Therapies in Medicine, 2017;30: 67-72.
98- Gligorov J, Ataseven B, Verrill M, et al;SafeHer Study Group. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study’s primary an
“Kanser ve Genetik” kitap bölümü A. Nihat Bozcuk ile birlikte yazıldı. “Genetik”, Bölüm 15, 295-304, Palme Kitapçılık, Ekim 2000, Ankara, Türkiye.
Çevirilen kitap bölümü “Intoxication” bölümü, “Mosby’s Crash Course”, Chapter 39, 387-390, Güneş Kitapçılık, 2001, Ankara, Türkiye (İngilizce’den Türkçe’ye çeviri).
Ulusal toplantılarda 100’den fazla bildiri sunuldu.
1. Ustun H., Akca S., Altunbas H., Bozcuk H., Ciftci F., Balci MK. Relationship between the Complications of Type 2 Diabetes Mellitus and Corrected QT in ECG. Turkish Diabetes Annual, 1997; 12:193-5.
2. Akca S., Ustun H., Bozcuk H., Balci M.K., Yardimsever M., Ersoy F. 2 Years’ Experience in Akdeniz University Medical Faculty Intensive Care Unit. Cukurova University Medical Faculty Journal, Vol.23:2, 1998; 82-7.
3. Ustun H., Bozcuk H., Ustun M., Savas B. Comparison of antiemetic efficiency of ondansetron and metoclopramide in patients using non-cisplatin chemotherapy regimens.Turkish Oncology Journal 1999; 13(4): 109-11.
4. Bozcuk H, Coban E, Gelen T, Ozdogan M, Samur M, Savas B. An unusual case of massive hepatomegaly in a patient with peritoneal and pleural mesothelioma at the absence of hepatic involvement. Accepted by Acta Oncologica Turcica in 2001.
5. Ataman F, Korcum AF, Bozcuk H, Şen CA, Samur M, Savas B, Aktan S. Postoperative adjuvant chemotherapy in the management of rectum cancer. The journal for the diseases of colon and rectum, 2003; 13: 51-56.
6. Ataman F, Şimşir V, Şen CA, Bozcuk H, Öğüş M, Erdoğan O, Savaş B. Preliminary results of pancreatic cancer patients with unresectable disease undergoing combined chemoradiotherapy. Accepted by The Journal of Şişli Etfal Hospital, in 2004
1.Ersoy F.F., Karayalcin U., Karayalcin B., Sapan M., Suleymanlar G., Bozcuk H., Yakupoglu G. Transfer of Native Insulin through the Peritoneal Membrane during CAPD in Diabetic and Non-Diabetic Patients. Abstracts of the 15th Annual CAPD Conference, 1995;
2.Sapan M., Bozcuk H., Akbulut M., et al. Peritoneal Equilibrisation Test (PET) in CAPD patients. Kidney Int 48: (5), 1681-1681, 1995.
3.Aslan M., Yucel G., Bozcuk H., Savas B. The effect of recombinant human granulocyte/macrophage-colony-stimulating factor (rHu GM-CSF) and rHu G-CSF administration on neutrophil chemiluminescence assay in patients following cyclic chemotherapy. Free Radi
4.Bozcuk H., Turner B., Chan O., Reznek R., Ravi R., Hendry W. F., Oliver R.T.D. The response on CT 21 days after chemotherapy as a predictor of the need for surgery in germ cell cancer. The Brit J Urol, Vol.81, (Suppl. 3), 1998; 5.
5.Ustun H., Ersoy F.F., Bozcuk H., Akca S., Sezer T., Suleymanlar G., Yakupoglu G. The effect of Cefodizime on peritoneal neutrophil and monocyte chemotaxis in CAPD patients. Abstracts of the 18th Annual CAPD Conference, 1998; 18: 1.
6.Mulatero C. W., Bozcuk H., Oliver R.T.D., Mair G., Nargund V. Bladder sparing with synchronous combination chemo/radiotherapy in invasive bladder cancer. Ann Oncol 9:62-62, Suppl.4, 1998.
7.Turner BP., Sohaib SA., Hanson J.,Bozcuk H.,Oliver R.T.D., Reznek R.H. Is 3D measurement of tumour volume valid, accurate and helpful technique in assessing response to chemotehrapy? European Radiology 1999; 9:supplement 1,abst 955.
8.Owen N.J., Tsetis D., Bozcuk H., Oliver R.T.D., Reznek R.H. Day 21 Computrised Tomography Scan Response as a Predictor of Need for Post Chemotherapy Surgery in Nonseminomatous Germ Cell Tumour. Radiology 213 P: 306-306, 1999.
9.Bozcuk H, Uslu G, Karaveli S, Samur M, Ozdogan M, Savas B. Predictors of distant metastasis at presentation in breast cancer: A retrospective study also evaluating associations among common biological indicators. Ann Oncol 11:37-37, Suppl.4, 2000.
10.Bozcuk H., Martin C. Does treatment delay affect survival in Non- Small Cell Lung Cancer? ESTRO 2000
11.Bozcuk H., Martin WMC. Does treatment delay affect survival in Non- Small Cell Lung Cancer? A retrospective analysis of delay and other factors. Brit J Cancer 83:43-43, Suppl. 1, 2000.
12.Bozcuk H, Samur M, Ozdogan M, Yildiz M, Savas B. Determinants of quality of life in a group of cancer patients in Turkey. MASCC 2001.
13.Kurtoğlu AU, Yücel G, Ataman F, Bozcuk H. The respiratory burst activity of neutrophils in patients of lung cancer treated by radiotherapy. Free Radical Bio Med 33: 75 Suppl. 1, 2002.
14.Bozcuk H, Samur M, Koyuncu E, Yıidız M, Özdoğan M, Savaş B. A prediction model for the risk of intrahospital death in cancer patients: does it really work? Proc Am Soc Clin Oncol, Vol 21(1): 379-379, 2002.
15.Yalçın B, Üner A, Akbulut H, İçli F, Işıkdoğan A, Büyükçelik A, Dinçol D, Demirkazık A, Bozcuk H. A new schedule of Mitomycin-C and Vinorelbine combination in patients with metastatic breast cancer resistant to anthracyclines and taxanes: A phase II st
16.Savaş B, Tanyel E, Bozcuk H, Yeşilipek A, Karadoğan İ, Küpesiz A, Kurdoğlu E, Ündar L. Using MTT in vitro drug sensitivity test for the prediction of chemotherapy failure of lekemia patients. Ann Oncol 13:17-17, Suppl 5, 2002.
17.Ataman F, Uğur A, Yücel G, Bozcuk H, Şimşir V. Effect of fractionated regional external beam radiotherapy on neutrophil subpopulations (in peripheral blood count) of cancer patients. Radiotherapy and Oncology 64:200-200, Suppl 1, 2002.
18.Bozcuk H, Uslu G, Akan I, Samur M, Ozdogan M, Yildiz M, Artac M,Ozben T, Savas B. The association of chemotherapy response in metastatic breast cancer with growth factor pathways. Proc Am Soc Clin Oncol, Vol 22: A 149, 37-37, 2003.
19.Samur M, Bozcuk H, Ozdogan M, Yildiz M, Artac M, Savas B. What influences weight gain during adjuvant chemotherapy in women with breast cancer? Proc Am Soc Clin Oncol, Vol 22: A 292, 73-73, 2003.
20.Savas B, Bozcuk H, Ozdogan M, Karaveli F, Pe E, Artaç M, Aykut A, Samur M. Molecular and clinical parameters which determine the docetaxel response in metastatic breast cancer. Proc Am Soc Clin Oncol, Vol 23: A 9732, 888-888, 2004.
21.Bozcuk H, Dalmiş B, Samur M, Savas B, Ozdogan M, Artac M, Yildiz M. Are baseline performance status and line of chemotherapy administration important for palliation of metastatic non-small cell lung cancer (NSCLC) with chemotherapy? Proc Am Soc Clin O
22.Bozcuk H, Gumus A, Ozbilim G, Sarper A, Ozdogan M, Artac M, Samur M, Savas B. Recursive partitioning analysis of selected molecular markers to predict mediastinal lymph node involvement in operable NSCLC. Proc Am Soc Clin Oncol, A 7320, 2005.
23.Aksu G, Bozcuk H, Korcum A, Sen CA. Does radiotherapy technique influence survival in rectal cancer? A multivariate analysis. Eur J Cancer supplements, A 704, 2005.
24.Ozdogan M, Samur M, Artac M, Yildiz M, Savas B, Bozcuk H. Factors effecting the disclosure practice of physicians treating cancer patients in Turkey.. Eur J Cancer supplements, A 1331, 2005.
25.Artac M, Pehlivan S, Akcan S, Pehlivan M, Gelen T, Itirli G, Aksoy NH, Ozdogan M, Savas B, Bozcuk H. The value of pharmacogenomic analysis of microsatellite instability (MSI) and XPD, XRCC1 genotype polymorphisms to predict clinical outcome in metastat
26.Bozcuk H, Artac M, Akcan S, Korgun DK, Ozben T, Ozdogan M, Samur M, Mutlu H, Kargi A, Savas B. Does serum VEGF predict prognosis in metastatic colorectal carcinoma patients treated with XELIRI? Proc Am Soc Clin Oncol, A 13548, 2006.
27.Artac M, Bozcuk H, Afacan B, Ozdogan M, Timur M, Yildiz M, Samur M, Savas B. Metronomic cyclophosphamide – etoposide chemotherapy and serum VEGF level in metastatic breast cancer patients. Ann Oncol 17: 86-86, Suppl 9, 2006.
28.Artac M, Samur M, Bozcuk H, Afacan B, Ozdogan M. The impact of waist to hip ratio on survival in metastatic breast cancer patients treated with aromatase inhibitors. Proc Am Soc Clin Oncol, A 1070, 2007.
29.Bozcuk HS, Ozdogan M, Artac M, Yildiz M. Correlates of benefit from induction chemotherapy before radiotherapy in non-small cell lung cancer (NSCLC): a meta-analytical approach with meta-regression analysis. Proc Am Soc Clin Oncol, A 7575, 2008.
30.Bozcuk H, Yildiz M, Ozdogan M, Coskun HS, Kargı A, Mutlu H, Uysal M, Savas B. Determinants of health service satisfaction among cancer patients and their caregivers in oncology services: a survey study bfrom two teaching hospitals in Turkey. Eur J Canc
31.Ozdogan M, Bozcuk H, Ozcan K, Tekeli A, Coskun HS, Kara A, Mutlu H, Kargı A, Uysal M, Savas B. The cancer education nursing unit’s impact on informational needs of cancer patients-the first Turkish report. Eur J Cancer supplements, A 4242, 2009.
32.Bozcuk H, Mutlu H, Artac M, Ozdogan M, Coskun HS, Kargı A, Uysal M, Savas B. An encouraging chemotherapy regimen in progressive small cell lung cancer. Eur J Cancer supplements, A 9130, 2009
33.Ozdogan M, Kargı A, Artac M, Bozcuk H, Boruban MC, Coskun HS, Mutlu H, Eren OO, Uysal M, Savas B. Maintenance semi-metronomic oral cyclophosphamide and oral etoposide regimen in extensive stage small-cell lung cancer patients after responding to first
34.Artac M, Bozcuk H, Kıyıcı A, Eren OO, Boruban MC, Ozdogan M. Correlation of serum leptin level and waist-to-hip ratio with overall survival of patients with metastatic breast cancer treated with aromatase inhibitors. Proc Am Soc Clin Oncol, A 1106, 20
35.Bozcuk H, Yildiz M, Ozdogan M, Coskun HS, Kaya C, Cakal S, Mutlu A, Ulukal E, Ay S, Kilickaya P. The associates of the risk of febrile neutropenia after conventional dose chemotherapy in patients witrh common cancers. A prospective study from two terti
36.Artac M, Askin D, Kiyici A, Eren OO, Oncel M, Boruban MC, Bozcuk H. Does obesity change the effect of aromatase inhibitors (AIs) on estradiol, leptin, insulin, and IGF-1 serum levels in breast cancer patients? J Clin Oncol 30, 2012 (suppl; abstr e110
37.Uysal M, Bozcuk H, Goksu SS, Tatli AM, Arslan D, Gunduz S, Coskun HS, Ozdogan M, Savas B. Proteinuria as a predictive factor in metastatic colorectal cancer patients treated with bevacizumab. J Clin Oncol 30, 2012 (suppl; abstr e14070)
38.Tatlı AM, Coşkun HS, Uysal M, Goksu SS, Arslan D, Gunduz S, Ozdogan M, Bozcuk H, Savas B. Capecitabine plus bevacizumab as a maintenance treatment after induction treatment with folfiri plus bevacizumab in metastatic colon cancer. J Clin Oncol 31, 2013
39.Bozcuk H, Yıldız M, Ucar S, Mutlu H, Coskun HS. The correlates of dose reduction in chemotherapy for patients with common cancers. A prospective study. Ann Oncol 2014; 25 (suppl_4): iv58-iv84. 10.1093/annonc/mdu326
40.Avcı F, Merdin A, Gunduz S, Boz cuk H, Coskun H. Opioid endocrinopathy: a clinical problem in cancer patients with pain. Ann Oncol 2014; 25 (suppl_4): iv517-iv541. 10.1093/annonc/mdu356
41.Bozcuk H, Ozcan K, Erdogan C, Mutlu H, Coskun HS. Effects of painting art therapy on quality of life and depression in cancer patients: a comparative study. J Clin Oncol 32, 2014 (suppl; abstr e17583)
42.Artac M, Geredeli C, Yıldırım S, Dede I, Inal A, Guler T, Boruban MC, Zamani AG, Demirkazık A, Bozcuk H. Relation of metastatic stage at the diagnosis of NSCLC to XRCC1 and TP53 SNPs. J Clin Oncol 2014: e19109.
43.Gligorov j,Bines J, Alba E, Mustachi G, Cinieri S, Gupta V, Pierga JY, Bozcuk H, Gaafar R, Gupta S, Vivanco GL, Wang X, Costa R, Altundag K, Chmielowska E, Ducla S, Freudensprung U, Cortes P, Doval D. Overall survival in the IMELDA randomized phase III
44.Doval D, Cinieri S, Bozcuk H, Pierga JY, Altundag K, Wang X, Gupta S, Vivanco GL, Chmielowska E, Bines J, Montcuquet P, Namour A, Alba E, Mustacchi G, Cortes P, Ducla S, Freudensprung U, Fallowfield L, Gligorov J. Exploratory post hoc analyses of patie
45.Ergen SA, Dincbas HF, Metcalfe E, Akyürek S, Yavas G, Ulger S, Ozdemir BS, Yucel B, Oksuz DC, Senocak M, Bozcuk H. Patterns of failure and prognostic factors of the patients with LD SCLC according to the TNM staging. TOG-TROD study. J Thoracic Oncol 20
1. Ustun H., Akca S., Altunbas H., Bozcuk H., Ciftci F., Balci MK. Relationship between the Complications of Type 2 Diabetes Mellitus and Corrected QT in ECG. Turkish Diabetes Annual, 1997; 12:193-5.
2. Akca S., Ustun H., Bozcuk H., Balci M.K., Yardimsever M., Ersoy F. 2 Years’ Experience in Akdeniz University Medical Faculty Intensive Care Unit. Cukurova University Medical Faculty Journal, Vol.23:2, 1998; 82-7.
3. Ustun H., Bozcuk H., Ustun M., Savas B. Comparison of antiemetic efficiency of ondansetron and metoclopramide in patients using non-cisplatin chemotherapy regimens.Turkish Oncology Journal 1999; 13(4): 109-11.
4. Bozcuk H, Coban E, Gelen T, Ozdogan M, Samur M, Savas B. An unusual case of massive hepatomegaly in a patient with peritoneal and pleural mesothelioma at the absence of hepatic involvement. Accepted by Acta Oncologica Turcica in 2001.
5. Ataman F, Korcum AF, Bozcuk H, Şen CA, Samur M, Savas B, Aktan S. Postoperative adjuvant chemotherapy in the management of rectum cancer. The journal for the diseases of colon and rectum, 2003; 13: 51-56.
6. Ataman F, Şimşir V, Şen CA, Bozcuk H, Öğüş M, Erdoğan O, Savaş B. Preliminary results of pancreatic cancer patients with unresectable disease undergoing combined chemoradiotherapy. Accepted by The Journal of Şişli Etfal Hospital, in 2004